Cargando…

Stem cell treatment and cerebral palsy: Systemic review and meta-analysis

BACKGROUND: Perinatal complications may result in life-long morbidities, among which cerebral palsy (CP) is the most severe motor disability. Once developed, CP is a non-progressive disease with a prevalence of 1-2 per 1000 live births in developed countries. It demands an extensive and multidiscipl...

Descripción completa

Detalles Bibliográficos
Autores principales: Eggenberger, Simone, Boucard, Céline, Schoeberlein, Andreina, Guzman, Raphael, Limacher, Andreas, Surbek, Daniel, Mueller, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6828595/
https://www.ncbi.nlm.nih.gov/pubmed/31692977
http://dx.doi.org/10.4252/wjsc.v11.i10.891
_version_ 1783465381662294016
author Eggenberger, Simone
Boucard, Céline
Schoeberlein, Andreina
Guzman, Raphael
Limacher, Andreas
Surbek, Daniel
Mueller, Martin
author_facet Eggenberger, Simone
Boucard, Céline
Schoeberlein, Andreina
Guzman, Raphael
Limacher, Andreas
Surbek, Daniel
Mueller, Martin
author_sort Eggenberger, Simone
collection PubMed
description BACKGROUND: Perinatal complications may result in life-long morbidities, among which cerebral palsy (CP) is the most severe motor disability. Once developed, CP is a non-progressive disease with a prevalence of 1-2 per 1000 live births in developed countries. It demands an extensive and multidisciplinary care. Therefore, it is a challenge for our health system and a burden for patients and their families. Recently, stem cell therapy emerged as a promising treatment option and raised hope in patients and their families. AIM: The aim is to evaluate the efficacy and safety of stem cell treatment in children with CP using a systematic review and meta-analysis METHODS: We performed a systematic literature search on PubMed and EMBASE to find randomized controlled clinical trials (RCT) investigating the effect of stem cell transplantation in children with CP. After the review, we performed a random-effects meta-analysis focusing on the change in gross motor function, which was quantified using the gross motor function measure. We calculated the pooled standardized mean differences of the 6- and/or 12-mo-outcome by the method of Cohen. We quantified the heterogeneity using the I-squared measure. RESULTS: We identified a total of 8 RCT for a qualitative review. From the initially selected trials, 5 met the criteria and were included in the meta-analysis. Patients’ population ranged from 0.5 up to 35 years (n = 282). We detected a significant improvement in the gross motor function with a pooled standard mean difference of 0.95 (95% confidence interval: 0.13-1.76) favoring the stem cell group and a high heterogeneity (I(2) = 90.1%). Serious adverse events were rare and equally distributed among both intervention and control groups. CONCLUSION: Stem cell therapy for CP compared with symptomatic standard care only, shows a significant positive effect on the gross motor function, although the magnitude of the improvement is limited. Short-term safety is present and further high-quality RCTs are needed.
format Online
Article
Text
id pubmed-6828595
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-68285952019-11-05 Stem cell treatment and cerebral palsy: Systemic review and meta-analysis Eggenberger, Simone Boucard, Céline Schoeberlein, Andreina Guzman, Raphael Limacher, Andreas Surbek, Daniel Mueller, Martin World J Stem Cells Meta-Analysis BACKGROUND: Perinatal complications may result in life-long morbidities, among which cerebral palsy (CP) is the most severe motor disability. Once developed, CP is a non-progressive disease with a prevalence of 1-2 per 1000 live births in developed countries. It demands an extensive and multidisciplinary care. Therefore, it is a challenge for our health system and a burden for patients and their families. Recently, stem cell therapy emerged as a promising treatment option and raised hope in patients and their families. AIM: The aim is to evaluate the efficacy and safety of stem cell treatment in children with CP using a systematic review and meta-analysis METHODS: We performed a systematic literature search on PubMed and EMBASE to find randomized controlled clinical trials (RCT) investigating the effect of stem cell transplantation in children with CP. After the review, we performed a random-effects meta-analysis focusing on the change in gross motor function, which was quantified using the gross motor function measure. We calculated the pooled standardized mean differences of the 6- and/or 12-mo-outcome by the method of Cohen. We quantified the heterogeneity using the I-squared measure. RESULTS: We identified a total of 8 RCT for a qualitative review. From the initially selected trials, 5 met the criteria and were included in the meta-analysis. Patients’ population ranged from 0.5 up to 35 years (n = 282). We detected a significant improvement in the gross motor function with a pooled standard mean difference of 0.95 (95% confidence interval: 0.13-1.76) favoring the stem cell group and a high heterogeneity (I(2) = 90.1%). Serious adverse events were rare and equally distributed among both intervention and control groups. CONCLUSION: Stem cell therapy for CP compared with symptomatic standard care only, shows a significant positive effect on the gross motor function, although the magnitude of the improvement is limited. Short-term safety is present and further high-quality RCTs are needed. Baishideng Publishing Group Inc 2019-10-26 2019-10-26 /pmc/articles/PMC6828595/ /pubmed/31692977 http://dx.doi.org/10.4252/wjsc.v11.i10.891 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Meta-Analysis
Eggenberger, Simone
Boucard, Céline
Schoeberlein, Andreina
Guzman, Raphael
Limacher, Andreas
Surbek, Daniel
Mueller, Martin
Stem cell treatment and cerebral palsy: Systemic review and meta-analysis
title Stem cell treatment and cerebral palsy: Systemic review and meta-analysis
title_full Stem cell treatment and cerebral palsy: Systemic review and meta-analysis
title_fullStr Stem cell treatment and cerebral palsy: Systemic review and meta-analysis
title_full_unstemmed Stem cell treatment and cerebral palsy: Systemic review and meta-analysis
title_short Stem cell treatment and cerebral palsy: Systemic review and meta-analysis
title_sort stem cell treatment and cerebral palsy: systemic review and meta-analysis
topic Meta-Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6828595/
https://www.ncbi.nlm.nih.gov/pubmed/31692977
http://dx.doi.org/10.4252/wjsc.v11.i10.891
work_keys_str_mv AT eggenbergersimone stemcelltreatmentandcerebralpalsysystemicreviewandmetaanalysis
AT boucardceline stemcelltreatmentandcerebralpalsysystemicreviewandmetaanalysis
AT schoeberleinandreina stemcelltreatmentandcerebralpalsysystemicreviewandmetaanalysis
AT guzmanraphael stemcelltreatmentandcerebralpalsysystemicreviewandmetaanalysis
AT limacherandreas stemcelltreatmentandcerebralpalsysystemicreviewandmetaanalysis
AT surbekdaniel stemcelltreatmentandcerebralpalsysystemicreviewandmetaanalysis
AT muellermartin stemcelltreatmentandcerebralpalsysystemicreviewandmetaanalysis